Ki16425

Ki16425 (Debio 0719) is a subtype-selective, competitive antagonist of the EDG-family receptors, LPA1 and LPA3 with Kis of 0.34 μM and 0.93 μM, respectively. Ki16425 (Debio 0719) reduces the LPA-induced activation of p42/p44 MAPK[1][2]. Ki16425 can also inhibit LPA-induced dephosphorylation of Yes-associated protein (YAP) /TAZ in HEK293A cells[3].

Product Specifications

CAS Number

[355025-24-0]

Product Name Alternative

Debio 0719

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

LPL Receptor; YAP

Type

Reference compound

Related Pathways

GPCR/G Protein; Stem Cell/Wnt

Applications

Cancer-Kinase/protease

Field of Research

Neurological Disease; Cancer

Assay Protocol

https://www.medchemexpress.com/ki16425.html

Purity

98.88

Solubility

DMSO : ≥ 100 mg/mL

Smiles

ClC1=C(C=CC=C1)C(C)OC(NC2=C(ON=C2C)C3=CC=C(C=C3)CSCCC(O)=O)=O

Molecular Formula

C23H23ClN2O5S

Molecular Weight

474.96

Precautions

H302, H315, H319, H335

References & Citations

[1]Ohta H, et al. Ki16425, a subtype-selective antagonist for EDG-family lysophosphatidic acid receptors.Mol Pharmacol, 2003, 64 (4), 994-1005.|[2]Moughal NA, et al. Protean agonism of the lysophosphatidic acid receptor-1 with Ki16425 reduces nerve growth factor-induced neurite outgrowth in pheochromocytoma 12 cells. J Neurochem, 2006, 98 (6), 1920-1929.|[3]Ma L, et al. Evidence for lysophosphatidic acid 1 receptor signaling in the early phase of neuropathic pain mechanisms in experiments using Ki-16425, a lysophosphatidic acid 1 receptor antagonist. J Neurochem, 2009, 109 (2), 603-610.|[4]Yu FX, et al. Regulation of the Hippo-YAP pathway by G-protein-coupled receptor signaling. Cell. 2012 Aug 17;150 (4) :780-91.